--- title: Formulation Development Packages for LNP & PNP description: Discover Curapath’s formulation screening and development packages for LNP & PNP systems,flexible, cost-effective solutions for drug delivery development. --- [![White](https://resources.curapath.com/hs-fs/hubfs/White.png?width=1063&height=400&name=White.png "White")](https://curapath.com/) Resources # Formulation Development Packages for LNP & PNP (Screening, Analytics & Stability) [Back to resources](https://resources.curapath.com/en/curapath-resource-library?hsLang=en) [Check other formulation packages](https://resources.curapath.com/plga-nanoparticles-formulation-packagespla-?hsLang=en) ### Discover Curapath’s structured approach to LNP and PNP formulation development. Our tiered packages combine screening, analytical rigor and stability strategies tailored for early discovery through preclinical readiness. Form ## Fill Out The Form To Begin Your Download Curapath has launched a tiered suite of Formulation Development Packages to accelerate the design and optimization of Lipid Nanoparticle (LNP) and Polymer Nanoparticle (PNP) systems for nucleic acid and peptide delivery. These packages, Essential, Advanced, and Expert, are built to offer increasing levels of complexity, analytical depth, and formulation flexibility. ![Formulation Development Services MA (1)](https://resources.curapath.com/hs-fs/hubfs/Formulation%20Development%20Services%20%20MA%20(1).png?width=1414&height=2000&name=Formulation%20Development%20Services%20%20MA%20(1).png) Each package includes access to proprietary and alternative lipids and polymers, enabling the development of high-quality, non-viral drug delivery systems tailored to a wide variety of payloads. From rapid formulation screening and foundational analytics to reporter gene assays and full characterization studies, Curapath’s packages are designed to meet the evolving needs of preclinical and clinical-stage programs. **Learn how these customizable, cost-effective solutions can support your formulation goals and streamline early-stage development. Download the complete overview of our formulation** **packages here.** ## What you’ll get in the download ### A clear and structured overview of Curapath’s formulation development services, designed to help you quickly assess the scope, depth and flexibility of our LNP and PNP packages. **In this document, you will find:** - A detailed comparison of **formulation development packages for [lipid nanoparticles (LNPs) and polymer nanoparticles (PNPs)](https://curapath.com/non-viral-gene-delivery/)**, from Essential to Expert level - An overview of our **formulation screening strategies**, including the number of formulations evaluated and selection criteria - The **[analytical dept](https://curapath.com/analytics-and-metrics/)h available per package**, covering key parameters such as particle size, PDI, encapsulation efficiency, nucleic acid content and identity testing - **Stability study design options**, including number of samples, timepoints and customized storage conditions - Available options to support **FTO-driven formulation strategies**, industry standards and access to **innovative excipients and shielding solutions**, including PEG alternatives - Optional **in vitro evaluation capabilities** to support data-driven candidate selection and preclinical readiness All packages are designed with [**scalability, CMC strategy and GMP-readiness**](https://curapath.com/end-to-end-services/#clinical)in mind, enabling a smooth transition from early formulation development toward advanced preclinical programs. Formulation Development Packages ## Frequently asked Questions ##### [About Curapath What is Curapath?](https://resources.curapath.com/en/curapath-formulations-development-packages-2026#collapse1-widget_1768812868390) [Curapath](https://curapath.com/about-us/)is a European Contract Development and Manufacturing Organization (CDMO) specialized in lipid- and polymer-based delivery systems. We support biotech and pharmaceutical companies from early development through GMP-ready manufacturing. Our core expertise includes polymer and lipid excipients, lipid nanoparticles (LNPs), polymer nanoparticles (PNPs), polymer–drug conjugates, and coating polymers. ##### [Formulation Development Services What kind of Formulation development packages are available?](https://resources.curapath.com/en/curapath-formulations-development-packages-2026#collapse2-widget_1768812868390) In this page you will find the packages for both **LNPs and PNPs.** There are options availble for [PLGA-PLA nanoparticles ](https://resources.curapath.com/plga-nanoparticles-formulation-packagespla-?hsLang=en) ##### [Formulation Development services Do you offer FTO formulations?](https://resources.curapath.com/en/curapath-formulations-development-packages-2026#collapse3-widget_1768812868390) YYes. Within our formulation development packages, we offer options designed to support[freedom-to-operate (FTO)](https://resources.curapath.com/en/curapath-curapath-certest-next-generation-lnps?hsLang=en) strategies, as well as industry-standard formulations. In addition, we provide access to a library of innovative components, including alternative shielding polymers, ionizable lipids and functional polymers, to support differentiated formulation design   ##### [Formulation Development services Does Curapath develop PEG alternatives?](https://resources.curapath.com/en/curapath-formulations-development-packages-2026#collapse4-widget_1768812868390) Yes. Curapath develops and manufactures [**PEG alternatives**](https://resources.curapath.com/en/curapath-product-catalog?hsLang=en) for drug delivery applications, including advanced polymers designed to address limitations associated with PEGylation, such as immunogenicity and long-term safety concerns. ##### [Formulation Development services Is this document suitable for early-stage biotech and advanced programs](https://resources.curapath.com/en/curapath-formulations-development-packages-2026#collapse5-widget_1768812868390) Absolutely. The document is designed for biotech and pharma teams working at different stages, **from early formulation feasibility to advanced preclinical programs** requiring deeper analytical and in vitro evaluation. ##### [Formulation Development services Can Curapath develop targeted lipid nanoparticles (tLNPs)?](https://resources.curapath.com/en/curapath-formulations-development-packages-2026#collapse6-widget_1768812868390) Yes. Curapath has strong expertise in the development and manufacturing of **targeted lipid nanoparticles (tLNPs)** designed to enable **extrahepatic delivery**. We support targeted LNP programs through a **fully integrated workflow**, covering formulation development, surface functionalization, analytical characterization and GMP-ready manufacturing. Our LNPs can be targetted to your desired target for intance we can create aesily T-cell targetted LNPs To know more about our conjuation ligand visit our partners website: [Cristal therapeutics](https://cristaltherapeutics.com/)   ##### [Formulation Development services What analytical techniques are included in the formulation development process?](https://resources.curapath.com/en/curapath-formulations-development-packages-2026#collapse7-widget_1768812868390) Depending on the selected package, analytical characterization may include particle size and PDI, encapsulation efficiency, nucleic acid content, identity testing, and stability assessment under customized conditions.   ##### [Formulation Development services Can these packages be adapted to my specific project needs?](https://resources.curapath.com/en/curapath-formulations-development-packages-2026#collapse8-widget_1768812868390) Absolutely. All formulation development packages can be customized based on your payload (nucleic acids, peptides or small molecules), target product profile, delivery route, and development stage. [Contact](https://curapath.com/contact-us/) ## Resources ### [CDMO Brochure Optimize Your Formulation Processes and Fill & Finish Requests with Robust Precision Lipid and Polymer Services ](https://resources.curapath.com/en/curapath-cdmo-brochure-download?hsLang=en) ### [pSar White Paper Polysarcosine (pSar), a safer, more effective alternative to poly-ethylene glycol (PEG)](https://resources.curapath.com/en/curapath-psar-white-paper-download?hsLang=en) ### [Next generation LNPs formulation with Certest’s and Curapath’s proprietary excipients](https://resources.curapath.com/en/curapath-curapath-certest-next-generation-lnps?hsLang=en) [](https://resources.curapath.com/en/curapath-curapath-certest-next-generation-lnps?hsLang=en) Certest and Curapath have joined forces to develop a novel LNP formulation leveraging the complementary Benefits of their proprietary excipients   ### [Polymeric Nanoparticles Case Study Development of a Highly Efficient, Biodegradable, Polymeric, Non-viral Vector (NVV) Platform for Nucleic Acid Delivery](https://resources.curapath.com/en/curapath-pol-nano-case-study?hsLang=en) ### [Curapath-Knauer Application Note Development and Optimization of LNP Formulations using the NanoScaler](https://resources.curapath.com/en/curapath-knauer-app-note?hsLang=en) ### [pSar-VitE General Excipient Case Study Development of PEG-free Excipients for Drug Delivery](https://resources.curapath.com/en/vite-psar-general-excipient?hsLang=en) ### [Curapath-Knauer Services Flyer LNP Formulation and Analytical Services](https://resources.curapath.com/en/curapath-knauer-flyer-download?hsLang=en) ![Lipid-Nanopeptide_0](https://resources.curapath.com/hs-fs/hubfs/Lipid-Nanopeptide_0.png?width=500&height=500&name=Lipid-Nanopeptide_0.png) Support for Your Therapeutic Program ### Contact a Chemist Today Contact Us, and we can discuss your specific therapeutic program and how Curapath can help build the right solution to advance your unique drug. [Contact Us](https://curapath.com/?page_id=151) ![footer-Logo](https://resources.curapath.com/hubfs/footer-Logo.svg "footer-Logo") [End-to-End Services](https://curapathstg.wpenginepowered.com/end-to-end-services/) [Expertise](https://curapathstg.wpenginepowered.com/expertise/) [Non-Viral Gene Delivery](https://curapathstg.wpenginepowered.com/non-viral-gene-delivery/) [Polymer & Lipid Excipients](https://curapathstg.wpenginepowered.com/polymer-lipid-excipients/) [Analytics & Metrics](https://curapathstg.wpenginepowered.com/analytics-and-metrics/) [Products](https://20205171.hs-sites.com/en/curapath-product-catalog?hsLang=en) [Resources](https://20205171.hs-sites.com/en/curapath-resource-library?hsCtaTracking=fca93105-47df-4ecb-8060-ab8c884fed09%7C49317d58-fe6c-4c70-83cc-d920d6200f8d&hsLang=en) [About Us](https://curapath.com/about-us/) [Contact](https://curapath.com/contact-us/) [Testimonials](https://curapath.com/testimonials/) [News & Events](https://curapath.com/news-events/) [Careers](https://curapath.com/careers/) [Privacy](https://curapath.com/privacy-policy/) [Cookie Policy](https://curapath.com/cookies-policy/) [Legal Notice](https://curapath.com/legal-notice/) US Commercial Offices One Broadway, 14th Floor Cambridge, MA 02142 USA GMP Production Site & Headquarters Av. Benjamin Franklin 19 46980 Paterna, Valencia Spain Innovation & Development Site C/Alexander Graham Bell 6 46980 Paterna, Valencia Spain [![In-White-96@2x-1](https://resources.curapath.com/hs-fs/hubfs/In-White-96@2x-1.png?width=30&height=30&name=In-White-96@2x-1.png "In-White-96@2x-1")](https://www.linkedin.com/company/curapath/) Copyright © 2024 Curapath. All rights reserved. ```json { "@context" : "https://schema.org", "@type" : "FAQPage", "mainEntity" : [ { "@type" : "Question", "acceptedAnswer" : { "@type" : "Answer", "text" : "Curapath is a European Contract Development and Manufacturing Organization (CDMO) specialized in lipid- and polymer-based delivery systems. We support biotech and pharmaceutical companies from early development through GMP-ready manufacturing. Our core expertise includes polymer and lipid excipients, lipid nanoparticles (LNPs), polymer nanoparticles (PNPs), polymer–drug conjugates, and coating polymers." }, "name" : "What is Curapath?" }, { "@type" : "Question", "acceptedAnswer" : { "@type" : "Answer", "text" : "On this page, you will find formulation development packages for both LNPs and PNPs. Options are available for a wide range of systems, including PLGA–PLA nanoparticles, and can be tailored to different development stages and project needs." }, "name" : "What kind of formulation development packages are available?" }, { "@type" : "Question", "acceptedAnswer" : { "@type" : "Answer", "text" : "Yes. Within our formulation development packages, we offer options designed to support freedom-to-operate (FTO) strategies, as well as industry-standard formulations. In addition, we provide access to a library of innovative components, including alternative shielding polymers, ionizable lipids and functional polymers, to support differentiated formulation design." }, "name" : "Do you offer FTO formulations?" }, { "@type" : "Question", "acceptedAnswer" : { "@type" : "Answer", "text" : "Yes. Curapath develops and manufactures PEG alternatives for drug delivery applications, including advanced polymer-based solutions designed to address limitations associated with PEGylation, such as immunogenicity and long-term safety concerns." }, "name" : "Does Curapath develop PEG alternatives?" }, { "@type" : "Question", "acceptedAnswer" : { "@type" : "Answer", "text" : "Absolutely. This document is designed for biotech and pharma teams working at different stages, from early formulation feasibility studies to advanced preclinical programs requiring deeper analytical characterization and in vitro evaluation." }, "name" : "Is this document suitable for early-stage biotech and advanced programs?" }, { "@type" : "Question", "acceptedAnswer" : { "@type" : "Answer", "text" : "Yes. Curapath has strong expertise in the development of targeted lipid nanoparticles (tLNPs) designed to enable extrahepatic delivery. Our integrated workflow combines rational lipid selection, controlled surface functionalization and advanced conjugation strategies to incorporate targeting ligands while preserving LNP stability, reproducibility and scalability. This approach supports the development of tLNPs directed toward challenging tissues and cell types such as lungs, T cells, brain or bone marrow, with CMC and GMP-readiness considered from the earliest stages. To learn more about our ligand conjugation capabilities, please visit our partner Cristal Therapeutics." }, "name" : "Can Curapath develop targeted lipid nanoparticles (tLNPs)?" }, { "@type" : "Question", "acceptedAnswer" : { "@type" : "Answer", "text" : "Depending on the selected package, analytical characterization may include particle size and PDI, encapsulation efficiency, nucleic acid content, identity testing, and stability assessment under customized conditions." }, "name" : "What analytical techniques are included in the formulation development process?" }, { "@type" : "Question", "acceptedAnswer" : { "@type" : "Answer", "text" : "Absolutely. All formulation development packages can be customized based on your payload (nucleic acids, peptides or small molecules), target product profile, delivery route and development stage." }, "name" : "Can these packages be adapted to my specific project needs?" } ] } ```